Thanks to all of our initial investors and our new investors, we have successfully reached our initial fund raising goal and are rapidly moving forward. Our lab progress is on schedule. With these funds, we will complete the preparation of the recombinant form of our anti-HIV monoclonal antibody followed by verification that its effectiveness is equivalent to that of the parent antibody. Most significantly, we are in discussions with a renowned international Bio-Pharma company who is interest in partnering and leading the next steps of animal trials and clinical trials. We are well on our way to the successful progress we have always expected. Your support and confidence is making this possible. We thank you.

Charles Cotropia, CEO BioClonetics